Skip to main content

Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Delayed Price · USD
11.07
-0.06 (-0.54%)
After-hours:Oct 21, 2021 5:20 PM EDT
11.13
1.12 (11.13%)
At close: Oct 21, 4:00 PM
Market Cap125.03M
Revenue (ttm)n/a
Net Income (ttm)-9.07M
Shares Out216.27M
EPS (ttm)-0.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,051,699
Open10.50
Previous Close10.02
Day's Range10.36 - 12.46
52-Week Range8.46 - 2,700.80
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About CMMB

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

IndustryBiotechnology
Founded2004
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolCMMB
Full Company Profile

Financial Performance

Financial Statements

News

Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascula...

TEL AVIV, Israel, Sept. 27, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.

3 weeks ago - PRNewsWire

Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer

TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.

1 month ago - PRNewsWire

Chemomab to Participate in Upcoming September Investor Conferences

TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd.

1 month ago - PRNewsWire

Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

TEL AVIV, Israel, Aug. 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibros...

2 months ago - PRNewsWire

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeuti...

3 months ago - PRNewsWire

Chemomab Therapeutics Is Heating Up And Could See A Move Soon

Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.

4 months ago - Benzinga

Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)

TEL AVIV, Israel, June 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibro...

4 months ago - PRNewsWire

Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

TEL-AVIV, Israel, May 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...

5 months ago - PRNewsWire

Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit

TEL AVIV, Israel, May 12, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...

5 months ago - PRNewsWire

Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)

TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...

5 months ago - PRNewsWire

Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing

TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...

6 months ago - PRNewsWire

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing

Anchiano s hareholders approve all resolutions at shareholder meeting

7 months ago - GlobeNewsWire

Why Immunovant, Anchiano, OpGen Are Rallying Today

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Other symbols:IMVTOPGN
7 months ago - Benzinga

ANCN Stock: Speculation Around Investor Letter Sends Anchiano Therapeutics Soaring

Anchiano Therapeutics (ANCN) stock is rocketing higher on Monday after a shareholder letter caught the interest of investors. The post ANCN Stock: Speculation Around Investor Letter Sends Anchiano Thera...

7 months ago - InvestorPlace

ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets Higher

ANCN stock is an early stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. The post ANCN Stock: 10 Things to Know as Anchiano Therapeutics R...

8 months ago - InvestorPlace

SHAREHOLDER ALERT: WeissLaw LLP Reminds CHNG, CPAH, CATM, and ANCN Shareholders About Its Ongoing Investigations

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...

Other symbols:CHNG
8 months ago - PRNewsWire

Lifshitz Law Firm, P.C. Announces Investigation of ANCN, BEAT, HMSY, SNCA, SPWH, TCP, TRP, TLRY, and APHA

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger o...

9 months ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("Anchiano" ...

10 months ago - PRNewsWire

ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting Higher Today

Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting H...

10 months ago - InvestorPlace

6 Health Care Stocks Trading With Low Price-Earnings Ratios

As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great va...

Other symbols:HAPPTMDIYCBDZCMD
10 months ago - GuruFocus

All You Need to Know About Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) Rating Upgrade to Buy

Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Anchiano Appoints Steve DiPalma as Chief Financial Officer

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPa...

1 year ago - GlobeNewsWire

Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 202...

1 year ago - GlobeNewsWire